RPE

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

Retrieved on: 
Monday, April 25, 2022
Cognition, Lewy body, Poster, ARVO, U.S. Securities and Exchange Commission, Association, Security (finance), Risk, NASDAQ, B cell, Geographic atrophy, Vance DeGeneres, Private Securities Litigation Reform Act, Central nervous system, Brain, AMD, Dementia, GLOBE, RPE, Patient, Cell, DLB, Retina, Association for Research in Vision and Ophthalmology, Degenerative disease, Therapy, Reading, Traffic barrier, Blood, Oxidative stress, Disease, Health, Research, Pharmaceutical industry, Ophthalmology

Cognition plans to initiate a Phase 2 clinical study for CT1812, the companys lead -2 receptor modulator, in patients with dry AMD.

Key Points: 
  • Cognition plans to initiate a Phase 2 clinical study for CT1812, the companys lead -2 receptor modulator, in patients with dry AMD.
  • Oxidative stress and toxic proteins such as amyloid-beta (A) oligomers have been implicated in the progression of dry AMD.
  • Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in the world, affecting approximately 190 million people.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Retrieved on: 
Monday, April 25, 2022
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Genetics, Clinical Trials, Patent, Medicine, Lineage, Â, Severe cognitive impairment, U.S. Securities and Exchange Commission, Security (finance), Hadassah Medical Center, PNC, Annual report, NYSE American, Retinitis pigmentosa, PNC Financial Services, Program, Degenerative disease, RPE, Cell, Infection, Retinal, Regenerative medicine, Retina, Efficiency, Injury, Hearing loss, Lineage Cell Therapeutics, Technology, Compte rendu, TASE, Auditory neuropathy, Method, Roche, SEC, Forward-looking statement, Retinal degeneration, Safety, Large-cell lung carcinoma, University Medical Center, VAC2, Risk, Transplant, Therapy, Hoffmann-La Roche, Cancer, Pharmaceutical industry, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage.
  • Notably, Lineage has demonstrated feasibility which could support a large-scale method for producing both types of photoreceptors, known as rods and cones.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

Retrieved on: 
Monday, March 14, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Optical, Science, Roche, Safety, AMD, Injury, Twitter, Incidence, Adult, Large-cell lung carcinoma, Wills Eye Hospital, Lineage Cell Therapeutics, Company, NYSE American, Research, Thomas Jefferson University, FACS, VAC2, FDA, Cell, CO, ARVO, Visual acuity, Cancer, Colorado Convention Center, Association, RPE, EMA, TASE, Infection, Retinal pigment epithelium, Severe cognitive impairment, Hoffmann-La Roche, Patient, European Medicines Agency, Eye, Vance DeGeneres, Method, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Food, Degenerative disease, Efficacy, Lineage, Pharmaceutical industry, Ophthalmology, Genentech, OpRegen, Dry AMD, Lineage Cell Therapeutics, Inc., OPREGEN, DRY AMD, LINEAGE CELL THERAPEUTICS, INC.

RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.

Key Points: 
  • RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.
  • The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC, by a group of 73 ophthalmologists.
  • ARVO is the largest and most respected eye and vision research organization in the world.
  • ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.

RPE Outsourcing Successfully Completes SOC 1 Type 2 Examination for 11th Consecutive Year

Retrieved on: 
Monday, February 28, 2022
RPE, GDPR, CMMC, Achievement, Compliance, CPA, State Board of Administration of Florida, PCI-DSS, Privacy, Better Business Bureau, SOC, SOC 1, Industry, ISO, Data center, Penetration test, Consultant, SOC 2, CCPA, Supply chain, CSA, ISO 27001, HITRUST, CEO, Software, Video game console, Computer security

Since 1999, RPE has been helping retailers integrate people, processes, and IT to deliver innovative merchandising and supply chain solutions.

Key Points: 
  • Since 1999, RPE has been helping retailers integrate people, processes, and IT to deliver innovative merchandising and supply chain solutions.
  • In today's retail landscape, businesses need to provide customers with a seamless shopping experience extending from brick-and-mortar stores to the online marketplace.
  • "At RPE, we make it a core competency to ensure that data protection is a pillar of our business.
  • Services provided include SOC 1, SOC 2, SOC 3, SOC for Cybersecurity, SOC for Supply Chain, CSA STAR, HIPAA/HITECH, ISO 27001, PCI-DSS, HITRUST CSF, Microsoft SSPA Attestation, Penetration Testing, GDPR, CCPA, CMMC and more.

Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

Retrieved on: 
Monday, January 24, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Forward-looking statement, Technology, Conference, RPE, VAC2, SEC, Outline, Interest, NYSE American, Roche, Lineage, Health care, Regenerative medicine, U.S. Securities and Exchange Commission, Agency for Healthcare Research and Quality, Infection, Lineage Cell Therapeutics, Therapy, Program, TASE, Company, Injury, Cancer, Risk, Compte rendu, VAC, Cell, Security (finance), Degenerative disease, Hoffmann-La Roche, Large-cell lung carcinoma, Annual report, Pharmaceutical industry, Genentech, Media

Interested parties can register to view both the live event and replay on the Events and Presentations section of Lineages website.

Key Points: 
  • Interested parties can register to view both the live event and replay on the Events and Presentations section of Lineages website.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
  • Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Retrieved on: 
Monday, December 20, 2021
Biotechnology, General Health, Pharmaceutical, Health, Therapy, NYSE American, IIA, Infection, Risk, RO, Disease, Injury, Trial of the century, ROG, Forward-looking statement, Lineage, RPE, Retinal pigment epithelium, Visual acuity, Incidence, Interest, U.S. Securities and Exchange Commission, Severe cognitive impairment, Safety, Security (finance), Program, Roche, Webcast, Investor, Cell, Development, Compte rendu, Lineage Cell Therapeutics, Cancer, Degenerative disease, SEC, Medicine, TASE, Vance DeGeneres, Geographic atrophy, Ophthalmology, Large-cell lung carcinoma, Method, Hoffmann-La Roche, Regenerative medicine, AMD, Company, Annual report, VAC2, Patient, Ageing, Technology, Pharmaceutical industry, Genentech, OpRegen, Lineage Cell Therapeutics, Inc., OPREGEN, LINEAGE CELL THERAPEUTICS, INC.

We are excited to partner with Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.

Key Points: 
  • We are excited to partner with Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Retrieved on: 
Tuesday, November 30, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Patient, Security (finance), Visual acuity, Retina, Retinal pigment epithelium, Lineage Cell Therapeutics, Safety, Cell, Annual report, Blood, Forward-looking statement, Company, Surgeon, Large-cell lung carcinoma, Injury, Cancer, NYSE American, Clinical trial, SEC, Human, Severe cognitive impairment, U.S. Securities and Exchange Commission, Vance DeGeneres, Food, Cohort, TASE, Atrophy, Degenerative disease, AMD, OCT, Drusen, Risk, Incidence, Geographic atrophy, FDA, Compte rendu, European Medicines Agency, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RPE, Infection, VAC2, Lineage, Method, Growth, Pharmaceutical industry, Health insurance, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients.

Key Points: 
  • After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients.
  • The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy.
  • We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population.
  • Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression.

$11+ Billion Respiratory Protection Equipment Markets - Global Forecasts from 2021 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 17, 2021
Health, Medical Supplies, Medical Devices, Heart, Adoption, Ageing, Safety, World Health Organization, FFP2, Overalls, MERS, Population, CAGR, World, Cancer, Prevalence, Power, Severe acute respiratory syndrome, Solution, Longevity, Ebola, Abdominal cavity, COVID-19, Mesothelioma, Asbestos, Critical care, Conditional sentence, Workplace, Research, Investment, N95, Risk, Oxygen, SARS, Disease, EVD, RPE, PPE, Growth, Statistics, Personal protective equipment

The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory protection equipment market is evaluated at US$ 6.879 billion for the year 2019 growing at a CAGR of 7.04% reaching the market size of US$ 11.076 billion by the year 2026.
  • Regulations by various governments involving workplace security are the major driving force for the global respiratory protection equipment market.
  • Several regulatory organizations have recommended various companies and governments to increase their manufacturing of respiratory protective equipment, including respirators and breathing apparatuses.

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Population, American Academy of Ophthalmology, Retinal pigment epithelium, Therapy, Anetoderma, COVID-19, Factor, Indiana University School of Medicine, Drug Quality and Security Act, Smoking, Risk, PK, Safety, Biomarker, Tissue, International Conference on Emerging Infectious Diseases, Western world, Social media, Securities Act of 1933, Forward-looking statement, RPE, Severe cognitive impairment, Clinical trial, Conference, Research, Geographic atrophy, Summit, Poster, Patient, FDA, Boat, Ageing, Choroid, Eye, Disease, Night vision, Twitter, American Academy, U.S. Securities and Exchange Commission, SEC, Pharmacokinetics, Retina, CNV, Reading, AAO, Vance DeGeneres, Annual report, AMD, CFH, File, Company, LinkedIn, Intravitreal injection, Complement, Nasdaq, Pharmaceutical industry, Medical device, Cryptocurrency, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.
  • In October 2021, Gemini announced a corporate restructuring including several executive officer transitions to prioritize assets and focus on initiating and executing GEM103s resource-intensive pivotal trial in GA.
  • At September 30, 2021, Gemini held $150.1 million in cash, $6.7 million of principal outstanding debt and 43.1 million shares outstanding.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies

Retrieved on: 
Tuesday, November 9, 2021
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Stem cell, University, RNA editing, Cancer, Inosine, Lists of diseases, MD, B cell, CEO, RNA, Potency (pharmacology), Technology, Research, Gamm, RPE, Partnership, Peking University, Doctor of Philosophy, University of Wisconsin–Madison, Adenosine, Translation, ADAR, Enzyme, Gene editing, Patient, Visual Science, Pharmaceutical industry, Vaccine, the David Gamm Laboratory, EdiGene, Inc, THE DAVID GAMM LABORATORY, EDIGENE, INC

LEAPER (Leveraging endogenous ADAR for programmable editing of RNA) employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR enzymes to change specific adenosine to inosine.

Key Points: 
  • LEAPER (Leveraging endogenous ADAR for programmable editing of RNA) employs short engineered ADAR-recruiting RNAs (arRNAs) to recruit native ADAR enzymes to change specific adenosine to inosine.
  • LEAPER is a robust, precise, and efficient RNA editing technology uniquely suited for in vivo therapies with broad therapeutic applicability.
  • This collaboration furthers our efforts in RNA editing and in vivo gene-editing therapies, said Dong Wei, Ph.D., CEO of EdiGene.
  • EdiGene is a global, clinical-stage biotechnology company focused on translating gene editing technologies into transformative therapies for patients with serious genetic diseases and cancer.